Abstract: Methods and systems for producing prescribed unit size poly(3-hydroxyalkanoate) (PHA) polymers and copolymers are provided. The methods and systems can employ recombinant bacteria that are not native producers of PHA or lack enzymes to degrade PHA once synthesized, metabolize short to long chain fatty acids without induction, and express an (R)-specific enoyl-CoA hydratase and a PHA synthase, the (R)-specific enoyl-CoA hydratase and PHA synthase having wide substrate specificities. The recombinant bacteria are fed at least one fatty acid substrate that is equal in carbon length to the prescribed or desired unit size of the PHA polymer to be produced. The prescribed unit size PHA that is produced is then isolated and/or purified.

Abstract: The present disclosure provides compositions that inhibit the SH2-containing inositol 5?-phosphatase (SHIP), as well as methods using such compositions for use in treating or ameliorating the effects of a medical condition in a subject.

Abstract: The invention provides complexes of Zn2+ of formulae (la) and (IIa) that are useful for treating cancer, as well as compositions and kits comprising such complexes.

Abstract: A cluster of nodes, comprising: a plurality of nodes, each having a security policy, and being associated task processing resources; a registration agent configured to register a node and issue a node certificate to the respective node; a communication network configured to communicate certificates to authorize access to computing resources, in accordance with the respective security policy; and a processor configured to automatically dynamically partition the plurality of nodes into subnets, based on at least a distance function of at least one node characteristic, each subnet designating a communication node for communicating control information and task data with other communication nodes, and to communicate control information between each node within the subnet and the communication node of the other subnets.

Abstract: Disclosed herein are RNA molecules with particular nucleotide sequences that, through Watson-Crick base pairing, enable the RNAs to form a hydrogel.

Abstract: Amino, amido, and heterocyclic compounds are disclosed. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diabetes complications, inflammation, and neurodegeneration, obesity, cancer, ischemia/reperfusion injury, cardiovascular disease and other diseases related to RAGE activity.

Abstract: A sensor including a layer of amorphous selenium (a-Se) and at least one charge blocking layer is formed by depositing the charge blocking layer over a substrate prior to depositing the amorphous selenium, enabling the charge blocking layer to be formed at elevated temperatures. Such a process is not limited by the crystallization temperature of a-Se, resulting in the formation of an efficient charge blocking layer, which enables improved signal amplification of the resulting device. The sensor can be fabricated by forming first and second amorphous selenium layers over separate substrates, and then fusing the a-Se layers at a relatively low temperature.

Abstract: Proteins that are differentially expressed or elevated in tissue and biofluids after central nervous system injuries are described. Elevated or reduced levels of the proteins, alone or in various combinations or ratios, can be used to assess severity of central nervous system injury (CNS injury) including traumatic brain injury (TBI), traumatic spinal cord injury (SCI) and chronic traumatic encephalopathy (CTE). Time course measurements post CNS-injury of these proteins can be used to monitor progress or recovery over periods up to several months. Differentiation of acute, subacute and chronic injury can be diagnosed by comparing the protein levels in CNS-injury patients at days 1-3, day 4-10 with levels at day 30-180 in comparison with normal controls.

Abstract: System, method, and accelerator to process a convolutional neural network. In accordance therewith, a tile structure having input data values is loaded for a convolution layer. Each tile of the tile structure corresponds to a respective feature map in a set of input feature maps. The tile structure of each iteration represents a different subset of data values in the input feature maps. Intermediate data values associated with a subset of the data values of the input feature maps in the current intermediate tile structure are reused, when the intermediate data values of a previous tile structure overlap values to be computed in the current tile structure. Intermediate non-overlapping data values that are associated with the subset of the data values in the current tile structure are computed using associated filters having weight data values. Available reused intermediate data values and computed intermediate data values are buffered as intermediate data.

Abstract: Membranes suitable for use in membrane distillation are provided. Such membranes may include nano-fibrous layers with adjustable pore sizes. The membranes may include a hydrophobic nano fibrous scaffold and a thin hydrophilic protecting layer that can significantly reduce fouling and scaling problems.

Abstract: The present invention relates to the use of SHIP1 inhibitors and pan-SHIP1/2 inhibitors in various methods, including, without limitation, a method of inhibiting SHIP to induce broad activation of natural killer (NK) cells to treat various diseases.

Abstract: Compositions and methods for the treatment of malignancy are disclosed.

Abstract: Oral compositions and methods of use thereof are provided herein. The oral compositions comprise a first component comprising at least one Eh-raising compound and a pharmaceutically acceptable carrier, and a second component comprising at least one zinc compound, an anti-microbial agent and a pharmaceutically acceptable carrier.

Abstract: The present invention provides a compound having the structure: and use of the compound for inhibiting the growth of or killing

Abstract: A composition used to form the active layer of a solar cell or hydrogen fuel cell that comprises, consists of or consists essentially of a homogenous dispersion, poly(3-hexylthiophene-2,5-diyl) (P3HT) and 1-(3-methoxycarbonyl)propyl-1-phenyl[6,6]C61 (PCBM). The homogenous dispersion comprises, consists of or consists essentially of graphene oxide (GO) or reduced graphene oxide (RGO) and sulfonated polystyrene (PSS) or para-methoxy-N-methylamphetamine (PMMA). The GO or RGO can be functionalized with a metal, preferably gold (Au), platinum (Pt), palladium (Pd) or ferric oxide (Fe2O3).

Abstract: There is set forth herein a method including building an interposer base structure on a first wafer having a first substrate, wherein the building an interposer base structure includes fabricating a plurality of through vias that extend through the first substrate and fabricating within an interposer base dielectric stack formed on the first substrate one or more metallization layer; building a photonics structure on a second wafer having a second substrate, wherein the building a photonics structure includes fabricating within a photonics device dielectric stack formed on the second substrate one or more photonics device; and bonding the photonics structure to the interposer base structure to define an interposer having the interposer base structure and one or more photonics device fabricated within the photonics device dielectric stack.

Abstract: The current disclosure describes methods for identifying subjects that would benefit from treatment with a chemotherapeutic agent. The disclosure is based in part on the observation that miR-129 expression levels are reduced in colorectal cancer. Accordingly, the current disclosure provides therapeutic compositions and methods for altering the expression of a miR-129 effector. Described herein are methods for characterizing the stage of colorectal cancer in a subject, based on the levels of miR-129 expression. The disclosure also identifies miR-129 as a predictive biomarker for cancer diagnosis and the subsequent treatment with directed therapeutic agents including but not limited to miR-129 nucleic acid molecules and/or a chemotherapeutic agent. The current disclosure also identifies novel therapeutic agents that modulate the level of BCL2, TS and/or E2F3 expression, as well as sensitize a subject to treatment with a chemotherapeutic agent.

Abstract: Isolated non-naturally occurring, mutant-human islet amyloid polypeptides (hIAPP) are disclosed. These polypeptides can be formulated or co-formulated at physiological pH, which enable the polypeptides of the instant disclosure to be delivered to a subject having an amyloid-based disease in a single injection with an insulin agent. Methods and compositions for treating amyloid-based disease in a subject in need thereof, by administering an effective amount of an isolated, mutant-hIAPP polypeptide, including formulations or co-formulations thereof are also disclosed.

Abstract: This invention relates to the field of energy storage devices, and especially electrochemical energy storage devices including electrolytes comprising an ionic liquid, one or more solvents, and one or more salts of a Group 2 element. Effects on electrochemical performance of the electrolyte of each of the components of the electrolyte were systematically determined. In addition, interactions between the electrolytes and separator films were dissected to optimize electrochemical performance of coin cell batteries.

Abstract: The invention generally relates to a purified inactivated Zika virus (ZIKV), methods for producing the purified inactivated ZIKV, immunogenic compositions and vaccines comprising the purified inactivated ZIKV and methods for the prevention and/or treatment of infection by ZIKV.